Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells
Targeted therapies have broadened the treatment landscape for colorectal cancer (CRC), highlighting the need for rational combination strategies. Although sorafenib and GW5074 show therapeutic promise and lidocaine may sensitise cancer cells to treatment, the mechanisms underlying these combinations...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2026-12-01
|
| Rangatū: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Ngā marau: | |
| Urunga tuihono: | https://www.tandfonline.com/doi/10.1080/14756366.2026.2678755 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|